These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 38003353)

  • 21. Anatomical Differences in Sphenoid Sinus During Endoscopic Transsphenoidal Surgery: Comparison Between Nonfunctioning Pituitary Neuroendocrine Tumor (PiTNET) and Growth Hormone-Secreting PiTNET.
    Lo Bue E; Pesaresi A; Lacroce P; Portonero I; Antico A; De Marco R; Garbossa D; Penner F; Zenga F
    World Neurosurg; 2024 Oct; 190():e701-e706. PubMed ID: 39116943
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Endocrinological outcome following first time transsphenoidal surgery for GH-, ACTH-, and PRL-secreting pituitary adenomas.
    Kristof RA; Schramm J; Redel L; Neuloh G; Wichers M; Klingmüller D
    Acta Neurochir (Wien); 2002 Jun; 144(6):555-61; discussion 561. PubMed ID: 12111488
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human growth hormone and prolactin secreting pituitary adenomas analyzed by in situ hybridization.
    Lloyd RV; Cano M; Chandler WF; Barkan AL; Horvath E; Kovacs K
    Am J Pathol; 1989 Mar; 134(3):605-13. PubMed ID: 2466405
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Co-occurrence of Pituitary Neuroendocrine Tumors (PitNETs) and Tumors of the Neurohypophysis.
    Saeger W; von Schöning J; Flitsch J; Jautzke G; Bergmann M; Hagel C; Knappe UJ
    Endocr Pathol; 2021 Dec; 32(4):473-479. PubMed ID: 34129177
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Prognostic-Based Approach in Growth Hormone-Secreting Pituitary Neuroendocrine Tumors (PitNET): Tertiary Reference Center, Single Senior Surgeon, and Long-Term Follow-Up.
    Ferrés A; Reyes L; Di Somma A; Topczewski T; Mosteiro A; Guizzardi G; De Rosa A; Halperin I; Hanzu F; Mora M; Alobid I; Aldecoa I; Bargalló N; Enseñat J
    Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612263
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A clinicomorphological study of pituitary tumors associated with the clinical syndrome of acromegaly.
    Andreeva M; Georgiev T; Bosadjieva E; Karagiosov L; Karagiosov K; Tomova A; Matrosov P; Kirilov G; Diankov L; Christova T
    Exp Clin Endocrinol; 1991; 98(3):223-7. PubMed ID: 1778242
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical Characteristics, Diagnosis, and Treatment of Thyroid Stimulating Hormone-Secreting Pituitary Neuroendocrine Tumor (TSH PitNET): A Single-Center Experience.
    Heo J; Suh YL; Kim SH; Kong DS; Nam DH; Lee WJ; Kim ST; Hong SD; Ryu S; Lee YB; Kim G; Jin SM; Kim JH; Hur KY
    Endocrinol Metab (Seoul); 2024 Apr; 39(2):387-396. PubMed ID: 38311828
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plurihormonal Pituitary Neuroendocrine Tumors: Clinical Relevance of Immunohistochemical Analysis.
    Dumitriu-Stan RI; Burcea IF; Dobre R; Nastase VN; Ceausu RA; Raica M; Poiana C
    Diagnostics (Basel); 2024 Jan; 14(2):. PubMed ID: 38248047
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Subclinical adenomas in postmortem pituitaries: classification and correlations to clinical data.
    Buurman H; Saeger W
    Eur J Endocrinol; 2006 May; 154(5):753-8. PubMed ID: 16645024
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of tumor characteristics and pre- and postoperative hormone levels on hormonal remission following endoscopic transsphenoidal surgery in patients with acromegaly.
    Cardinal T; Rutkowski MJ; Micko A; Shiroishi M; Jason Liu CS; Wrobel B; Carmichael J; Zada G
    Neurosurg Focus; 2020 Jun; 48(6):E10. PubMed ID: 32480366
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Basic fibroblastic growth factor stimulates prolactin secretion from human anterior pituitary adenomas without affecting adenoma cell proliferation.
    Atkin SL; Landolt AM; Jeffreys RV; Diver M; Radcliffe J; White MC
    J Clin Endocrinol Metab; 1993 Sep; 77(3):831-7. PubMed ID: 8370706
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Plurihormonal (TSH-GH-prolactin Secreting) PIT-1-Positive pituitary Macroadenoma/Pituitary Neuroendocrine Tumor (PitNET) Associated with Graves' Disease: A Case Report.
    Morgante C; Guaraldi F; Asioli S; Mazzatenta D; Papi G; Pontecorvi A
    Endocr Metab Immune Disord Drug Targets; 2023; 23(12):1557-1561. PubMed ID: 37357515
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cortistatin inhibits growth hormone release from human fetal and adenoma pituitary cells and prolactin secretion from cultured prolactinomas.
    Rubinfeld H; Hadani M; Barkai G; Taylor JE; Culler MD; Shimon I
    J Clin Endocrinol Metab; 2006 Jun; 91(6):2257-63. PubMed ID: 16595604
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictors of postoperative biochemical remission in lower Knosp grade growth hormone-secreting pituitary adenomas: a large single center study.
    Zhang S; Chen J; Yao S; Akter F; Wang Z; Hu B; Zhu D; Duan C; Chen W; Zhu Y; Wang H; Mao Z
    J Endocrinol Invest; 2023 Mar; 46(3):465-476. PubMed ID: 36125731
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum prolactin and growth hormone response to thyrotropin-releasing hormone in patients with pituitary adenomas.
    Chang CC; Chen FW; Hsieh HC
    Taiwan Yi Xue Hui Za Zhi; 1989 May; 88(5):443-9. PubMed ID: 2507734
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunohistochemical Analyses of Mammalian Target of Rapamycin (mTOR) Expression in Pituitary Neuroendocrine Tumors (PitNETs): mTOR as a Therapeutic Target for Functional PitNETs.
    Nakazato I; Shiomi T; Oyama K; Matsuno A; Inomoto C; Yoshiyuki Osamura R
    Acta Histochem Cytochem; 2023 Dec; 56(6):121-126. PubMed ID: 38318106
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The sensitivity of growth hormone and prolactin secretion to the somatostatin analogue SMS 201-995 in patients with prolactinomas and acromegaly.
    Lamberts SW; Zweens M; Klijn JG; van Vroonhoven CC; Stefanko SZ; Del Pozo E
    Clin Endocrinol (Oxf); 1986 Aug; 25(2):201-12. PubMed ID: 2878748
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Growth hormone and prolactin gene expression in human densely and sparsely granulated somatotroph adenomas by in situ hybridization with digoxigenin-labeled probes.
    Yamada S; Takahashi M; Hara M; Sano T; Aiba T; Shishiba Y; Suzuki T; Asa SL
    Diagn Mol Pathol; 1994 Mar; 3(1):46-52. PubMed ID: 8162255
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gender Differences in Patients with Prolactinoma: Single-center Ukrainian Experience.
    Voznyak O; Zinkevych I; Lytvynenko A; Hryniv N; Ilyuk R; Kobyliak N
    Rev Recent Clin Trials; 2024; 19(3):204-214. PubMed ID: 38561622
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Age, GH/IGF-1 levels, tumor volume, T2 hypointensity, and tumor subtype rather than proliferation and invasion are all reliable predictors of biochemical response to somatostatin analogue therapy in patients with acromegaly: A clinicopathological study.
    Durmuş ET; Atmaca A; Kefeli M; Çalışkan S; Mete O; Aslan K; Fidan M; Çolak R; Durmuş B
    Growth Horm IGF Res; 2022 Dec; 67():101502. PubMed ID: 36115256
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.